Margaux Fresnais

Dr. Margaux Fresnais

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
CPCharles Pottier
Charles Pottier
MFMargaux Fresnais
Margaux Fresnais
MGMarie Gilon
Marie Gilon
GJGuy Jerusalem
Guy Jerusalem
Rémi LonguespéeRémi Longuespée
Rémi Longuespée
NSNor Eddine Sounni
Nor Eddine Sounni
Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limited by the appearance of resistance or adverse effects. In this review, we summarize the main features of RTKs and their inhibitors (RTKIs), their current use in oncology, and mechanisms of resistance. We also describe the technological advances of artificial intelligence, chemoproteomics, and microfluidics in elaborating powerful strategies that could be used in providing more efficient and selective small molecules inhibitors of RTKs. Finally, we discuss the interest of therapeutic combination of different RTKIs or with other molecules for personalized treatments, and the challenge for effective combination with less toxic and off-target effects.


1 April 2015 in Forensic Science International
Verified
Journal Article
Closed access
MFMargaux Fresnais
Margaux Fresnais
PRP. Richardin
P. Richardin
AGA. Gimat
A. Gimat
MSMarcela Sepulveda
Marcela Sepulveda
ELE. Leize-Wagner
E. Leize-Wagner
ACA. Charrié
A. Charrié

14 September 2018 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
Rémi LonguespéeRémi Longuespée
Rémi Longuespée
KKKatharina Kriegsmann
Katharina Kriegsmann
MCMartin Cremer
Martin Cremer
CZChristiane Zgorzelski
Christiane Zgorzelski
Rita CasadonteRita Casadonte
Rita Casadonte
Mark KriegsmannMark Kriegsmann
Mark Kriegsmann

23 July 2018 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
KKKatharina Kriegsmann
Katharina Kriegsmann
Rémi LonguespéeRémi Longuespée
Rémi Longuespée
MHMichael Hundemer
Michael Hundemer
CZChristiane Zgorzelski
Christiane Zgorzelski
RCRita Casadonte
Rita Casadonte
Mark KriegsmannMark Kriegsmann
Mark Kriegsmann

26 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
OBOlaf Beck
Olaf Beck
Claudia ParetClaudia Paret
Claudia Paret
ARAlexandra Russo
Alexandra Russo
JBJuergen Burhenne
Juergen Burhenne
MFMargaux Fresnais
Margaux Fresnais
JFJoerg Faber
Joerg Faber
Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we tested the effect of three IGF specific inhibitors and tested ceritinib as an off-target inhibitor, alone or in combination with dasatinib, on the proliferation of seven primary OS cells. Picropodophyllin, particularly in combination with dasatinib and the combination ceritinib/dasatinib were effective in abrogating the proliferation. The ceritinib/dasatinib combination was applied to the primary cells of a 16-year-old girl with a long history of lung metastases, and was more effective than cabozantinib and olaparib. Therefore, the combination was used to treat the patient. The treatment was well tolerated, with toxicity limited to skin rush and diarrhea. A histopathological evaluation of the tumor after three months of therapy indicated regions of high necrosis and extensive infiltration of macrophages. The extension of the necrosis was proportional to the concentration of dasatinib and ceritinib in the area, as analysed by an ultra performance liquid chromatography–tandem mass spectrometer (UPLC-MS/MS). After the cessation of the therapy, radiological analysis indicated a massive growth of the patient’s liver metastases. In conclusion, these data indicate that the combination of ceritinib/dasatinib is safe and may be used to develop new therapy protocols.